{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:19:33Z","timestamp":1794640773448,"version":"4.9.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F30 DA044700"],"award-info":[{"award-number":["F30 DA044700"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Commission Grant","award":["701698"],"award-info":[{"award-number":["701698"]}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"St. Paul\u2019s Foundation Scholar award"},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25-DA037756"],"award-info":[{"award-number":["R25-DA037756"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1 DA015815"],"award-info":[{"award-number":["UG1 DA015815"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.drugpo.2019.01.020","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T09:16:09Z","timestamp":1549876569000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Comparing Canadian and United States opioid agonist therapy policies"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-8177","authenticated-orcid":false,"given":"Kelsey C.","family":"Priest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gorfinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-0052","authenticated-orcid":false,"given":"Jan","family":"Klimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2019.01.020_bib0005","series-title":"Member handbook: Your guide to benefits and services","author":"AllCare Health Plan","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0010","series-title":"Drug coverage","author":"AllCare Health Plan","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0015","series-title":"Oregon effort to declare healthcare a right falters. Modern Healthcare","author":"Associated Press","year":"2018"},{"issue":"sup1","key":"10.1016\/j.drugpo.2019.01.020_bib0020","first-page":"S17","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0025","series-title":"Drug policy and the public good","author":"Babor","year":"2010"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0030","series-title":"More harm than good: Drug policy in Canada. Black point, Nova Scotia and Winnipeg","author":"Boyd","year":"2016"},{"issue":"1","key":"10.1016\/j.drugpo.2019.01.020_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12954-017-0152-3","article-title":"Telling our stories: Heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver","volume":"14","author":"Boyd","year":"2017","journal-title":"Harm Reduction Journal"},{"issue":"5","key":"10.1016\/j.drugpo.2019.01.020_bib0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/16066350009005592","article-title":"The expansion of methadone prescribing in Ontario, 1996\u20131998","volume":"8","author":"Brands","year":"2000","journal-title":"Addiction Research"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0045","series-title":"Did you know? B.C. Pharmacare covers opioid agonist treatment under Plan G","author":"British Columbia Centre on Substance Use","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0050","unstructured":"British Columbia (n.d.). How the Province is Responding. Retrieved from https:\/\/www2.gov.bc.ca\/gov\/content\/overdose\/how-the-province-is-responding."},{"key":"10.1016\/j.drugpo.2019.01.020_bib0055","series-title":"Guidance for injectable opioid agonist treatment for opioid use disorder","author":"British Columbia Centre on Substance Use","year":"2017"},{"issue":"9","key":"10.1016\/j.drugpo.2019.01.020_bib0060","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: A national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0065","series-title":"Regulations amending the narcotic control regulations and the new classes of practitioners regulations (diacetylmorphine (heroin) and methadone): SOR\/2018-37","author":"Canada Gazette","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0070","series-title":"OHP drug list (formulary)","author":"CareOregon","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0075","series-title":"Cascade Health Alliance drug formulary","author":"Cascade Health Alliance LLC","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0080","series-title":"Member handbook","author":"Cascade Health Alliance LLC","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0085","series-title":"2015\/2016 Annual report: Committed to better health through excellence in pharmacy","author":"College of Pharmacists of British Columbia","year":"2016"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0090","series-title":"ColumbiapPacific CCO: Member handbook","author":"Columbia Pacific CCO","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0095","series-title":"OHP drug list (formulary)","author":"Columbia Pacific Coordinated Care Organization","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1353\/bhm.2004.0066","article-title":"Drug wars: Policy hots and historical cools","volume":"78","author":"Courtwright","year":"2004","journal-title":"Bulletin of the History of Medicine"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0105","series-title":"Better prevention, treatment & recovery services","author":"Department of Health","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0110","series-title":"Title 21 code of federal regulations: Part 1306 \u2014 prescriptions","author":"Drug Enforcement Administration","year":"2005"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0115","unstructured":"Drug Enforcement Administration. (n.d.). Title 21 United States Code (USC) Controlled Substances Act: Part 1306 \u2014 prescriptions. General information \u00a71306.07 administering or dispensing of narcotic drugs. Retrieved from https:\/\/www.deadiversion.usdoj.gov\/21cfr\/21usc\/823.htm."},{"key":"10.1016\/j.drugpo.2019.01.020_bib0120","series-title":"Member handbook","author":"Eastern Oregon Coordinated Care Organization","year":"2018"},{"issue":"7","key":"10.1016\/j.drugpo.2019.01.020_bib0125","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0706743717711167","article-title":"The state of opioid agonist therapy in Canada 20 years after federal oversight","volume":"62","author":"Eibl","year":"2017","journal-title":"The Canadian Journal of Psychiatry"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0130","series-title":"NIHB newsletter: Fall 2014","author":"Express Scripts","year":"2014"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0135","series-title":"Subutex and Suboxone approved to treat opiate dependence","author":"Food and Drug Administration","year":"2002"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0140","series-title":"A study of effectiveness and financing of public and private drug treatment systems","author":"Gerstein","year":"1990"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0145","series-title":"Exemptions","author":"Government of Canada","year":"2015"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0150","series-title":"Regulations amending certain regulations made under the Controlled Drugs and Substances Act (access to diacetylmorphine for emergency treatment) P.C. 2016-759 August 26, 2016","author":"Government of Canada","year":"2016"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0155","series-title":"Controlled Drugs and Substances Act (S.C. 1996, c. 19)","author":"Government of Canada","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0160","series-title":"Oregon governor declares addiction, substance abuse public health crisis","author":"Guevarra","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0165","series-title":"The use of opioids in the management of opioid dependence","author":"Health Canada","year":"1992"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0170","series-title":"Methadone program","author":"Health Canada","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0175","series-title":"National consultation on the Section 56 exemption requirement for methadone prescribing","author":"Health Canada","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0180","series-title":"Member handbook","author":"Health Share of Oregon","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0185","series-title":"Health Share of Oregon\/Providence (OHP)","author":"Health Share of Oregon\/Providence","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0190","series-title":"NCHS data brief: No. 329: November 2018: Drug overdose deaths in the United States, 1999\u20132017","author":"Hedegaard","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0195","series-title":"Your mental health benefits","author":"InterCommunity Health Network CCO","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0200","series-title":"Your prescription drug benefits","author":"InterCommunity Health Network CCO","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0205","series-title":"Drug list (formulary)","author":"Jackson Care Connect","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0210","series-title":"Member handbook","author":"Jackson Care Connect","year":"2018"},{"issue":"10","key":"10.1016\/j.drugpo.2019.01.020_bib0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3928\/0048-5713-19751001-04","article-title":"The maintenance option and the special action office for drug abuse prevention","volume":"5","author":"Jaffe","year":"1975","journal-title":"Psychiatric Annals"},{"issue":"2","key":"10.1016\/j.drugpo.2019.01.020_bib0220","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.drugpo.2019.01.020_bib0225","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0230","series-title":"Hep-cats, narcs, and pipe dreams: A history of America's romance with illegal drugs","author":"Jonnes","year":"1996"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0235","series-title":"Formulary (covered drugs) Oregon and Washington","author":"Kaiser Permanente","year":"2018"},{"issue":"5","key":"10.1016\/j.drugpo.2019.01.020_bib0240","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.drugpo.2019.01.020_bib0245","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/ADM.0b013e318262a97a","article-title":"Financial factors and the implementation of medications for treating opioid use disorders","volume":"6","author":"Knudsen","year":"2012","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2019.01.020_bib0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0740-5472(02)00259-3","article-title":"History and current status of opioid maintenance treatments: Blending conference session","volume":"23","author":"Kreek","year":"2002","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0255","series-title":"Drug policies and problems: The promises and pitfalls of cross-national comparison","author":"MacCoun","year":"1993"},{"issue":"3","key":"10.1016\/j.drugpo.2019.01.020_bib0260","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.drugpo.2019.01.020_bib0265","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0270","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1146\/annurev-publhealth-040617-013526","article-title":"Treatment and prevention of opioid use disorder: Challenges and opportunities","volume":"39","author":"McCarty","year":"2018","journal-title":"Annual Review of Public Health"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0275","series-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","author":"McNicholas","year":"2004"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0280","series-title":"Physical health service delivery by eligibility group (December 2012-2016)","author":"Oregon Health Authority","year":"2016"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0285","series-title":"Oregon Health Plan (MCO and CCO) administrative rulebook: Chapter 410, division 141","author":"Oregon Health Authority","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0290","unstructured":"Oregon Health Authority (n.d.). Coordinated care: The Oregon difference. Retrieved from http:\/\/www.oregon.gov\/oha\/HPA\/Pages\/CCOs-Oregon.aspx."},{"key":"10.1016\/j.drugpo.2019.01.020_bib0295","series-title":"Buprenorphine\/naloxone versus methadone for the treatment of opioid dependence: A review of comparative clinical effectiveness, cost-effectiveness and guideline","author":"Ottawa Canadian Agency for Drugs and Technologies in Health","year":"2016"},{"issue":"8","key":"10.1016\/j.drugpo.2019.01.020_bib0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0305","series-title":"Formulary (drug list)","author":"PacificSource Community Solutions","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0310","series-title":"PacificSource coordinated care organization (CCO) (Your Oregon Health Plan coverage) central Oregon","author":"PacificSource Community Solutions","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0315","series-title":"PacificSource coordinated care organization (CCO): Your Oregon Health Plan coverage: Columbia gorge","author":"PacificSource Community Solutions","year":"2018"},{"issue":"3","key":"10.1016\/j.drugpo.2019.01.020_bib0320","first-page":"291","article-title":"Methadone treatment of opiate dependence in Canada","volume":"80","author":"Peachey","year":"1985","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0325","series-title":"Formulary","author":"PrimaryHealth","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0330","series-title":"Alcohol and drug treatment services","author":"PrimaryHealth","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0335","series-title":"Providence Crosstown Clinic","author":"Providence Health Care","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0340","series-title":"Federal regulation of methadone treatment","author":"Rettig","year":"1995"},{"issue":"1_suppl","key":"10.1016\/j.drugpo.2019.01.020_bib0345","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1177\/0033354918793627","article-title":"A public health strategy for the opioid crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Reports"},{"issue":"4","key":"10.1016\/j.drugpo.2019.01.020_bib0350","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.drugpo.2019.01.020_bib0355","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0360","series-title":"Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016. Drug and Alcohol Dependence, 189(1879-0046 (Electronic))","first-page":"90","author":"Socias","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0365","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0370","series-title":"National report: Apparent opioid-related deaths in Canada (January 2016 to December 2017) Web-based Report","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0375","series-title":"Policy paradox: The art of political decision making","author":"Stone","year":"2012"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0380","series-title":"Medicaid coverage and financing of medications to treat alcohol and opioid use disorders","author":"Substance Abuse and Mental Health Services Administration","year":"2014"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0385","series-title":"Federal guidelines for opioid treatment programs","author":"Substance Abuse and Mental Health Services Administration","year":"2015"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0390","series-title":"Oversight of opioid treatment program (OTP) accrediting bodies","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0395","series-title":"TIP 63: Medications for opioid use disorder","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0400","series-title":"Member handbook: Mental health","author":"Trillium Community Health Plan","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0405","series-title":"Trillium Formulary \u2013 Oregon Health Plan (list of covered drugs for 2018)","author":"Trillium Community Health Plan","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0410","series-title":"Open enrollment information","author":"Tuality Health Alliance","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0415","series-title":"Umpqua health: Oregon health plan","author":"Umpqua Health","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0420","series-title":"Umpqua health alliance","author":"Umpqua Health","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0425","author":"United Nations","year":"2013"},{"issue":"4","key":"10.1016\/j.drugpo.2019.01.020_bib0430","doi-asserted-by":"crossref","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of medicaid expansion on medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0435","series-title":"Western Oregon advanced health formulary 2018: By therapeutic class","author":"Western Oregon Advanced Health LLC","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0440","series-title":"Member handbook: 2016-2017","year":"2016"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0445","unstructured":"White House. (n.d.). The Opioid Crisis. Retrieved from https:\/\/www.whitehouse.gov\/opioids\/."},{"key":"10.1016\/j.drugpo.2019.01.020_bib0450","series-title":"Handbook","author":"Willamette Valley Community Health LLC","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0455","series-title":"WVCH quality coordinated care","author":"Willamette Valley Community Health LLC","year":"2017"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0460","series-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence (9789241547543)","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0465","series-title":"Yamhill community care organization: Member handbook","author":"Yamhill Community Care Organization","year":"2018"},{"key":"10.1016\/j.drugpo.2019.01.020_bib0470","series-title":"OHP drug list (formulary)","author":"Yamhill County Care Organization","year":"2018"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919300283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919300283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:47:26Z","timestamp":1760629646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919300283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":94,"alternative-id":["S0955395919300283"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.020","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Canadian and United States opioid agonist therapy policies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}